Case report: TP53 heterogeneous alteration in grade 3 type I gastric NET: a case implicating primary tumor progression.

Yan Li, Yuekui Bai, Hongjuan Ti, Chunyu Zhou, Qian Liu, Ying Dong

Abstract readCase Reports

In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan LiDepartment of Pathology, Haidian Hospital, Haidian District of Peking University Third Hospital, Beijing, China.

Yuekui BaiDepartment of General Surgery, Haidian Hospital, Haidian District of Peking University Third Hospital, Beijing, China.

Hongjuan TiDepartment of Pathology, Haidian Hospital, Haidian District of Peking University Third Hospital, Beijing, China.

Chunyu ZhouDepartment of Pathology, Haidian Hospital, Haidian District of Peking University Third Hospital, Beijing, China.

Qian LiuDepartment of Pathology, Haidian Hospital, Haidian District of Peking University Third Hospital, Beijing, China.

Ying DongDepartment of Pathology, Peking University First Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Grade 3(G3) type I gastric neuroendocrine tumors (NETs) are rare, with only three documented cases in the literature to our knowledge. The case we report involves a type I gastric NET(g-NET) classified as G3, which exhibits heterogeneity in TP53 gene mutations. This suggests that G3 g-NETs may develop from G2 forms. In this tumor located in the gastric body, both G2 and G3 components coexist. The G2 component is found in the superficial mucosa and submucosa, while the G3 component is in the submucosa and muscularis propria. Genetic testing reveals that the TP53 gene is mutated in the G3 component. The coexistence of these alterations within a single primary tumor is extremely rare, indicating that the TP53 gene plays a crucial role in the progression from G2 NET to G3 NET. This case may challenge our previous understanding of g-NETs.

Indexed as

autoimmune metaplastic atrophic gastritisgastric neuroendocrine tumor (GNET)neuroendocrine tumor grade 3pathological factorsTP53 mutation

Identifiers

PMID41426335

DOI10.3389/fonc.2025.1708609

PMCPMC12714645

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.